Rift Valley fever virus (RVFV), a member of the Bunyaviridae family, may cause severe hepatitis, encephalitis and haemorrhagic fever in humans. There are currently no available licensed vaccines or therapies to treat the viral infection in humans. RNA interference (RNAi)-based viral gene silencing offers a promising approach to inhibiting replication of this highly pathogenic virus. The small (S) segment of the RVFV tripartite genome carries the genetic determinates for pathogenicity during infection. This segment encodes the non-structural S (NSs) and essential nucleocapsid (N) genes.
Methods
To advance RNAi-based inhibition of RVFV replication, we designed several Pol III short hairpin RNA (shRNA) expression cassettes against the NSs and N genes, including a multimerized plasmid vector that included four shRNA expression cassettes.
Results
Effective target silencing was demonstrated using full- and partial-length target reporter assays, and confirmed by western blot analysis of exogenous N and NSs expression. Small RNA northern blots showed detectable RNAi guide strand formation from single and multimerized shRNA constructs. Using a cell culture model of RVFV replication, shRNAs targeting the N gene decreased intracellular nucleocapsid protein concentration and viral replication. The shRNAs directed against the NSs gene reduced NSs protein concentrations and alleviated NSs-mediated cytotoxicity, which may be caused by host transcription suppression.
Conclusions
These data are the first demonstration that RNAi activators have a potential therapeutic benefit for countering RVFV infection.
PetersC.J., LiuC.T., AndersonG.W., MorrillJ.C., JahrlingP.B.Pathogenesis of viral hemorrhagic fevers: Rift Valley fever and Lassa fever contrasted. Rev Infect Dis1989; 11Suppl 4: S743–S749.
3.
GerdesG.H.Rift valley fever. Vet Clin North Am Food Anim Pract2002; 18: 549–555.
4.
MillerB.R., GodseyM.S., CrabtreeM.B.Isolation and genetic characterization of Rift Valley fever virus from Aedes vexans arabiensis, Kingdom of Saudi Arabia. Emerg Infect Dis2002; 8: 1492–1494.
5.
JuppP.G., KempA., GrobbelaarA.The 2000 epidemic of Rift Valley fever in Saudi Arabia: mosquito vector studies. Med Vet Entomol2002; 16: 245–252.
6.
ShoemakerT., BoulianneC., VincentM.J.Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000–01. Emerg Infect Dis2002; 8: 1415–1420.
7.
FagboS.F.The evolving transmission pattern of Rift Valley fever in the Arabian Peninsula. Ann N Y Acad Sci2002; 969: 201–204.
8.
GadA.M., HassanM.M., el SaidS., MoussaM.I., WoodO.L.Rift Valley fever virus transmission by different Egyptian mosquito species. Trans R Soc Trop Med Hyg1987; 81: 694–698.
9.
TurellM.J., BaileyC.L., BeamanJ.R.Vector competence of a Houston, Texas strain of Aedes albopictus for Rift Valley fever virus. J Am Mosq Control Assoc1988; 4: 94–96.
10.
LimD.V., SimpsonJ.M., KearnsE.A., KramerM.F.Current and developing technologies for monitoring agents of bioterrorism and biowarfare. Clin Microbiol Rev2005; 18: 583–607.
11.
SidwellR.W., SmeeD.F.Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Res2003; 57: 101–111.
12.
BorioL., InglesbyT., PetersC.J.Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA2002; 287: 2391–2405.
13.
MüllerR., PochO., DelarueM., BishopD.H.L., BouloyM.Rift valley fever virus L segment: correction of the sequence and possible functional role of newly identified regions conserved in RNA-dependent polymerases. J Gen Virol1994; 75: 1345–1352.
14.
CollettM.S.Messenger RNA of the M segment RNA of Rift Valley fever virus. Virology1986; 151: 151–156.
15.
GiorgiC., AccardiL., NicolettiL.Sequences and coding strategies of the S RNAs of Toscana and Rift Valley fever viruses compared to those of Punta Toro, Sicilian Sandfly fever, and Uukuniemi viruses. Virology1991; 180: 738–753.
16.
VialatP., BillecocqA., KohlA., BouloyM.The S segment of Rift Valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice. J Virol2000; 74: 1538–1543.
17.
PerroneL.A., NarayananK., WorthyM., PetersC.J.The S segment of Punta Toro virus (Bunyaviridae, Phlebovirus) is a major determinant of lethality in the Syrian hamster and codes for a type I interferon antagonist. J Virol2007; 81: 884–892.
18.
KalveramB., LihoradovaO., IkegamiT.NSs protein of rift valley fever virus promotes posttranslational downregulation of the TFIIH subunit p62. J Virol2011; 85: 6234–6243.
19.
Le MayN., DubaeleS., De SantisL.P., BillecocqA., BouloyM., EglyJ-M. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell2004; 116: 541–550.
20.
Le MayN., MansurogluZ., LégerP.A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog2008; 4: e13.
21.
BouloyM., JanzenC., VialatP.Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol2001; 75: 1371–1377.
22.
BillecocqA., SpiegelM., VialatP.NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J Virol2004; 78: 9798–9806.
23.
IkegamiT., NarayananK., WonS., KamitaniW., PetersC.J., MakinoS.Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog2009; 5: e1000287.
24.
HabjanM., PichlmairA., ElliottR.M.NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol2009; 83: 4365–4375.
25.
MullerR., SaluzzoJ-F, LopezN.Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg1995; 53: 405–411.
26.
BirdB.H., AlbarinoC.G., HartmanA.L., EricksonB.R., KsiazekT.G., NicholS.T.Rift Valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol2008; 82: 2681–2691.
27.
LiuL., CelmaC., RoyP.Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins. Virol J2008; 5: 82.
28.
FireA., XuS., MontgomeryM.K., KostasS.A., DriverS.E., MelloC.C.Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature1998; 391: 806–811.
29.
ArbuthnotP.Harnessing RNA interference for the treatment of viral infections. Drug News Perspect2010; 23: 341–350.
30.
FowlerT., BambergS., MollerP.Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol2005; 86: 1181–1188.
31.
MüllerS., GuntherS.Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus. Antimicrob Agents Chemother2007; 51: 2215–2218.
32.
GeisbertT.W., HensleyL.E., KaganE.Postexposure protection of Guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis2006; 193: 1650–1657.
33.
GeisbertT.W., LeeA.C., RobbinsM.Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet2010; 375: 1896–1905.
34.
FlusinO., VigneS., PeyrefitteC.N., BouloyM., CranceJ.M., IseniF.Inhibition of Hazara nairovirus replication by small interfering RNAs and their combination with ribavirin. Virol J2011; 8: 249.
35.
TakedaA., SugiyamaK., NaganoH.Identification of a novel RNA silencing suppressor, NSs protein of tomato spotted wilt virus. FEBS Lett2002; 532: 75–79.
36.
SoldanS.S., PlassmeyerM.L., MatukonisM.K., Gonzalez-ScaranoF.La Crosse virus nonstructural protein NSs counteracts the effects of short interfering RNA. J Virol2005; 79: 234–244.
37.
PassmanM., WeinbergM., KewM., ArbuthnotP.In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem Biophys Res Commun2000; 268: 728–733.
38.
BertrandE., CastanottoD., ZhouC.The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA1997; 3: 75–88.
39.
SaaymanS., BarichievyS., CapovillaA., MorrisK.V., ArbuthnotP., WeinbergM.S.The efficacy of generating three independent anti-HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA. PLoS ONE2008; 3: e2602.
40.
KingP., GoodbournS.The beta-interferon promoter responds to priming through multiple independent regulatory elements. J Biol Chem1994; 269: 30609–30615.
41.
Jansen van VurenP., PaweskaJ.T.Laboratory safe detection of nucleocapsid protein of Rift Valley fever virus in human and animal specimens by a sandwich ELISA. J Virol Methods2009; 157: 15–24.
42.
GrimmD., WangL., LeeJ.S.Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest2010; 120: 3106–3119.
43.
ArbuthnotP.Harnessing RNA interference for the treatment of viral infections. Drug News Perspect2010; 23: 341–350.
44.
BirdB.H., BawiecD.A., KsiazekT.G., ShoemakerT.R., NicholS.T.Highly sensitive and broadly reactive quantitative reverse transcription-PCR assay for high-throughput detection of Rift Valley fever virus. J Clin Microbiol2007; 45: 3506–3513.
45.
NjengaM.K., PaweskaJ., WanjalaR.Using a field quantitative real-time PCR test to rapidly identify highly viremic Rift Valley fever cases. J Clin Microbiol2009; 47: 1166–1171.
46.
IkegamiT., WonS., PetersC.J., MakinoS.Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J Virol2006; 80: 2933–2940.
47.
MansurogluZ., JosseT., GilleronJ.Nonstructural NSs protein of Rift Valley fever virus interacts with pericentromeric DNA sequences of the host cell, inducing chromosome cohesion and segregation defects. J Virol2010; 84: 928–939.
48.
MandellR.B., FlickR.Rift Valley fever virus: an unrecognized emerging threat?Hum Vaccin2010; 6: 597–601.
49.
VerbruggenP., RufM., BlakqoriG.Interferon antagonist NSs of La Crosse virus triggers a DNA damage response-like degradation of transcribing RNA polymerase II. J Biol Chem2011; 286: 3681–3692.
50.
GrimmD., KayM.A.Combinatorial RNAi: a winning strategy for the race against evolving targets?Mol Ther2007; 15: 878–888.
51.
ter BrakeO., KonstantinovaP., CeylanM., BerkhoutB.Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther2006; 14: 883–892.
52.
McintyreG.J., GronemanJ.L., YuY.H., TranA., ApplegateT.L.Multiple shRNA combinations for near-complete coverage of all HIV-1 strains. AIDS Res Ther2011; 8: 1.
53.
HenryS.D., van der WegenP., MetselaarH.J., TilanusH.W., ScholteB.J., van der LaanL.J.Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther2006; 14: 485–493.
54.
GouD., WengT., WangY.A novel approach for the construction of multiple shRNA expression vectors. J Gene Med2007; 9: 751–763.
